drugset
drugset / Trial / NCT04828265

Study of Aldafermin (NGM282) in Healthy Adult Male Japanese and Non-Japanese Subjects

NCT04828265 ↗

Phase 1 Completed 36 enrolled NGM Biopharmaceuticals, Inc
RandomizedParallel-groupOpen-labelTreatment

Summary

This is an open-label study to assess safety, tolerability, and pharmacokinetics of Aldafermin (NGM282) in healthy adult male Japanese and non-Japanese subjects

Timeline

Start
2021-04-13
Primary completion
2021-07-06
Completion
2021-07-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Aldafermin Protein / enzyme biologic 0.3 mg Subcutaneous
Subject Aldafermin Protein / enzyme biologic 1 mg Subcutaneous
Subject Aldafermin Protein / enzyme biologic 3 mg Subcutaneous

Indications

No indication recorded.